Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > Regulatory News
Pharmya Logo
2014 September Sep 25

Revision 1- GVP Module VI- Management and Reporting of Adverse Reactions to Medicinal Products

    On 16 September 2014, a new revision of Module VI on  Management and Reporting of Adverse Reactions to Medicinal Products came into effect. GVP Module VI has been revised to provide clarification on the clock start for reporting…

Read more
Pharmya Logo
2014 April Apr 15

MHRA clarifies expedited reporting requirements for clinical trials

Published by MHRA on 09-Apr-2014 Individual case study reports (ICSRs) are being wrongly expedited to the MHRA as spontaneous cases. The guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal products; section…

Read more

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

In partnership with the region

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Relaunched EMA website now live
  • Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27-30 November 2023
  • ANSM publishes the 2022 haemovigilance activity report
Copyright © 2018 - Pharmya - Legal terms - Quality Policy